| Biomarker ID | 808 |
| PMID | 22078333 |
| Year | 2012 |
| Biomarker | Prostate Helth Index (phi) |
| Biomarker Basis | Concentration Based |
| Biomolecule | Protein |
| Source | Blood |
| Subjects | Humans |
| Regulation | Upregulated in Gleason Score ≥7 |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: OR: 1.052 (95% CI: 1.034–1.070); Multivariate: 1.047 (95% CI: 1.027–1.067); |
| Effect on Pathways | Pathways Include :-ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
| Experiment | Gleason Score ≥7 and Gleason Score <7 |
| Type of Biomarker | Prognostic |
| Cohort | 350 patients with prostate cancer were chosen. (n= 317) GS ≥ 7 and (n= 33) GS>7 |
| Senstivity | 90.8 % (95% CI: 86.6–94.0) |
| Specificity | 34.8% (95% CI: 25.0–45.7) |
| AUC | 0.74 |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | UniCel DxI800 Immunoassay System analyser (Beckman Coulter Inc., Brea, CA, USA) |
| Clinical | No |
| Remarks | Sensitivity, Specificity calculated at 3 different criterions |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | KLK3 |